SCHEMBL5135552

SCHEMBL5135552

CCCCN(Cc1cc([N+](=O)[O-])ccc1F)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
C5AR1 P21730 1/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TSPO P30536 2/20 0.36
OPRK1 P41145 1/20 0.36
BCHE P06276 3/20 0.35
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137350 0.88 CYP1A2 (0.44) LMNAC5AR1CYP1A2CYP2C9TDP1
SCHEMBL5135016 0.88 C5AR1 (0.41) C5AR1POLBTSPOMAPT
SCHEMBL5169689 0.87 C5AR1 (0.40) C5AR1MAPT
SCHEMBL5136908 0.87 C5AR1 (0.38) C5AR1BCHE
SCHEMBL5074315 0.84 C5AR1 (0.40) C5AR1POLBMAPT
SCHEMBL5074325 0.84 C5AR1 (0.39) C5AR1MAPT
SCHEMBL5134844 0.83 C5AR1 (0.44) C5AR1NPC1RAB9A
SCHEMBL5135665 0.83 CASR (0.38) C5AR1CYP1A2CYP2C9KMT2APOLB
SCHEMBL5135659 0.83 P2RX7 (0.41) C5AR1POLBTSPO
SCHEMBL5135155 0.82 C5AR1 (0.42) C5AR1TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed